Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Long

Showing results (51-60 of 1,617) with videos related to

Pageof 162
Sort By:
Parasites & Vectors|February 6, 2020
PfSWIB, a potential chromatin regulator for var gene regulation and parasite development in Plasmodium falciparumWei-Feng Wang, Yi-Long Zhang
Oncotargets and Therapy|December 16, 2020
Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with <i>EGFR-</i>Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial ProgramHai-Yan Tu, Yi-Long Wu
Future Oncology (London, England)|September 15, 2020
Afatinib for the first-line treatment of <i>EGFR</i> mutation-positive NSCLC in China: a review of clinical dataHai-Yan Tu, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 7, 2024
"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLCMei-Mei Zheng, Yi-Long Wu
The Lancet. Oncology|March 7, 2018
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' replyYi-Long Wu, Wen-Zhao Zhong
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences|September 27, 2025
[Research progress in the role of caspase<b>-</b>3 in regulating pyroptosis and apoptosis in non<b>-</b>alcoholic fatty liver disease]Saiying Cao, Yi Long, Lina Yang
Journal of Hematology & Oncology|October 12, 2012
Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysisChongrui Xu, Qing Zhou, Yi-Long Wu
The Lancet. Oncology|October 2, 2013
Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' replyTony S K Mok, Yi-Long Wu
The Journal of Organic Chemistry|October 12, 2002
Mild alpha-halogenation reactions of 1,3-dicarbonyl compounds catalyzed by Lewis acidsDan Yang, Yi-Long Yan, Bob Lui
Discovery Medicine|December 31, 2009
A small step towards personalized medicine for non-small cell lung cancerTony Mok, Yi-Long Wu, Li Zhang
Pageof 162

Showing results (51-60 of 1,617) with videos related to

Sort By:
Pageof 162
Parasites & Vectors|February 6, 2020
PfSWIB, a potential chromatin regulator for var gene regulation and parasite development in Plasmodium falciparumWei-Feng Wang, Yi-Long Zhang
Oncotargets and Therapy|December 16, 2020
Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with <i>EGFR-</i>Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial ProgramHai-Yan Tu, Yi-Long Wu
Future Oncology (London, England)|September 15, 2020
Afatinib for the first-line treatment of <i>EGFR</i> mutation-positive NSCLC in China: a review of clinical dataHai-Yan Tu, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 7, 2024
"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLCMei-Mei Zheng, Yi-Long Wu
The Lancet. Oncology|March 7, 2018
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' replyYi-Long Wu, Wen-Zhao Zhong
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences|September 27, 2025
[Research progress in the role of caspase<b>-</b>3 in regulating pyroptosis and apoptosis in non<b>-</b>alcoholic fatty liver disease]Saiying Cao, Yi Long, Lina Yang
Journal of Hematology & Oncology|October 12, 2012
Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysisChongrui Xu, Qing Zhou, Yi-Long Wu
The Lancet. Oncology|October 2, 2013
Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' replyTony S K Mok, Yi-Long Wu
The Journal of Organic Chemistry|October 12, 2002
Mild alpha-halogenation reactions of 1,3-dicarbonyl compounds catalyzed by Lewis acidsDan Yang, Yi-Long Yan, Bob Lui
Discovery Medicine|December 31, 2009
A small step towards personalized medicine for non-small cell lung cancerTony Mok, Yi-Long Wu, Li Zhang
Pageof 162